CJC-1295 / Ipamorelin

CJC-1295 / Ipamorelin is a combination of two peptides that stimulate growth hormone release through different, complementary mechanisms. CJC-1295 is a long-acting analogue of growth hormone-releasing hormone (GHRH), modified to resist degradation and, in its drug affinity complex form, to bind albumin for a circulating half-life of roughly 8 days ^[1][2]. Ipamorelin is a selective growth hormone secretagogue, a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as an agonist at the growth hormone secretagogue (ghrelin) receptor, mimicking the endogenous peptide ghrelin ^[3].

The rationale for pairing them is mechanistic synergy. A GHRH analogue increases the amount of growth hormone the pituitary is prepared to release, while a ghrelin-receptor agonist triggers release and amplifies the pulse, so combining the two produces a larger, cleaner GH response than either alone ^[3][5]. Ipamorelin was specifically notable at its discovery for its selectivity: unlike earlier secretagogues, it released growth hormone without significantly raising ACTH or cortisol ^[3].

This pairing is one of the most popular in applied peptide use for growth hormone support, body composition, and recovery, and it is commonly encountered in the context of physique and performance protocols ^[5]. Both components are also studied for legitimate clinical questions around GH deficiency and, for ipamorelin, gastrointestinal motility and appetite ^[4]. Regulatory status is investigational; neither peptide is an approved medicine for these uses, both are sold as research compounds, and they are prohibited in sport, with reviews emphasizing the uncertainties of unregulated products ^[5].

These are research peptides, not approved drugs, so they are legal to buy but not sold for human use. Pushing GH and IGF-1 up is not free; common effects are water retention, tingling or numbness in the hands, joint aches, and head-rush flushing after a dose. Raising IGF-1 chronically is the real concern; it can worsen insulin resistance and, in theory, feed existing tumors, so anyone with cancer history or active cancer should avoid it. Injection-site reactions are typical, and sterile technique matters. It is popular and generally well tolerated short term, but long-term data in healthy people using it for enhancement is thin.

The two peptides in this pairing come from separate pharmaceutical efforts. Ipamorelin was developed in the 1990s by the Danish company Novo Nordisk and first described in a 1998 study by Raun and colleagues as the first selective growth-hormone secretagogue, notable because, unlike earlier peptides, it released growth hormone without also raising cortisol or prolactin.

CJC-1295 originated in the early 2000s at the Canadian biotechnology firm ConjuChem, which applied its Drug Affinity Complex technology to attach a group that binds albumin in the bloodstream, dramatically extending the half-life of a growth-hormone-releasing hormone fragment. Neither compound is an approved medicine; both remain research peptides. Their combination, joining a long-acting GHRH analogue with a selective ghrelin-receptor agonist, was popularized within the peptide and performance communities on the pharmacological logic that the two act through distinct, complementary pathways to amplify the body's own growth-hormone pulse.

Among peptide enthusiasts, the CJC-1295 and Ipamorelin combination has achieved almost canonical status as the archetypal growth-hormone stack, and its reputation is built on sound pharmacology rather than mere popularity. The appeal lies in how cleanly the two peptides complement one another; CJC-1295 provides sustained GHRH signaling that can raise growth hormone and IGF-1 for days, while Ipamorelin delivers a sharp, selective pulse through the ghrelin receptor.

Ipamorelin's selectivity is the real star of the pairing, since it stimulates growth hormone release without the surges in stress hormones such as cortisol and ACTH that troubled older secretagogues, giving the stack its clean reputation. Because the two agents act on different receptors, their effects on growth-hormone release are additive, which is the elegant basis for combining them. As with any GH-axis intervention, an honest account notes the trade-offs; reported effects for the class include fluid retention, injection-site reactions, appetite changes, and shifts in glucose handling.